Fundraising FoxDomain Associates — 2015 Investments
7 investments dated 2015 · listed companies and verified rows first · show all
Aldeyra Therapeutics is a biopharmaceutical company developing therapies for eye diseases and other conditions.
BiotechHealthtechMedical DevicesLexington, US
Todd C. Brady(Executive Officer, Director)inStephen Tulipano(Executive Officer)inScott L. Young(Executive Officer)inDr. Brady(President and Chief Executive Officer)
BoardJesse I. Treu(Director)inBen Bronstein(Director)
Board seatJesse Treu· per SEC Form D
BiotechSan Mateo, US
Anthony Ford(Executive Officer)inMichael Kitt(Executive Officer)inKathleen Sereda Glaub(Executive Officer, Director)in
BoardKevin Starr(Director)inArthur Pappas(Director)Liam Ratcliffe(Director)
Board seatJesse Treu· per SEC Form D
Co-investorsPappas CapitalFidelity InvestmentsJennison AssociatesThird Rock Ventures
Currax Pharmaceuticals develops and markets a portfolio of therapies for chronic progressive diseases.
BiotechHealthtechLa Jolla, US
Preston Klassen(Executive Officer)inJoseph Hagan(Executive Officer)Michael Narachi(Executive Officer, Director)Thomas Cannell(Executive Officer)
BoardBrian H. Dovey(Director)in
Board seatBrian DoveyEckard Weber· per SEC Form D · $90M raise · filed Sep 2015
Co-investorsCross Creek AdvisorsMontreux Equity PartnersNew Enterprise Associates (NEA)Sofinnova VenturesDomain Partners
HealthtechDuluth, US
Anthony V. Lando(Executive Officer, Director)inTodd Meyer(Executive Officer)inDilip Paithanker(Executive Officer)Robert Leslie(Executive Officer)Dilip Paithankar(Executive Officer)in
BoardRebecca B. Robertson(Director)
Board seatJesse Treu· per SEC Form D
Co-investorsAccuitive Medical VenturesVersant Ventures
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.